FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126500640> ?p ?o ?g. }

• W3126500640 endingPage "889" @default.
• W3126500640 startingPage "889" @default.
• W3126500640 abstract "The authors in the current work suggested the potential repurposing of omarigliptin (OMR) for neurodegenerative diseases based on three new findings that support the preliminary finding of crossing BBB after a single dose study in the literature. The first finding is the positive results of the docking study with the crystal structures of A2A adenosine (A2AAR) and acetylcholine esterase (AChE) receptors. A2AAR is a member of non-dopaminergic GPCR superfamily receptor proteins and has essential role in regulation of glutamate and dopamine release in Parkinson’s disease while AChE plays a major role in Alzheimer’s disease as the primary enzyme responsible for the hydrolytic metabolism of the neurotransmitter acetylcholine into choline and acetate. Docking showed that OMR perfectly fits into A2AAR binding pocket forming a distinctive hydrogen bond with Threonine 256. Besides other non-polar interactions inside the pocket suggesting the future of the marketed anti-diabetic drug (that cross BBB) as a potential antiparkinsonian agent while OMR showed perfect fit inside AChE receptor binding site smoothly because of its optimum length and the two fluorine atoms that enables quite lean fitting. Moreover, a computational comparative study of OMR docking, other 12 DPP-4 inhibitors and 11 SGLT-2 inhibitors was carried out. Secondly, glucagon-like peptide-1 (GLP-1) concentration in rats’ brain tissue was determined by the authors using sandwich GLP-1 ELISA kit bio-analysis to ensure the effect of OMR after the multiple doses’ study. Brain GLP-1 concentration was elevated by 1.9-fold following oral multiple doses of OMR (5 mg/kg/day, p.o. for 28 days) as compared to the control group. The third finding is the enhanced BBB crossing of OMR after 28 days of multiple doses that had been studied using LC-MS/MS method with enhanced liquid–liquid extraction. A modified LC-MS/MS method was established for bioassay of OMR in rats’ plasma (10–3100 ng/mL) and rats’ brain tissue (15–2900 ng/mL) using liquid–liquid extraction. Alogliptin (ALP) was chosen as an internal standard (IS) due to its LogP value of 1.1, which is very close to the LogP of OMR. Extraction of OMR from samples of both rats’ plasma and rats’ brain tissue was effectively achieved with ethyl acetate as the extracting solvent after adding 1N sodium carbonate to enhance the drug migration, while choosing acetonitrile to be the diluent solvent for the IS to effectively decrease any emulsion between the layers in the stated method of extraction. Validation results were all pleasing including good stability studies with bias of value below 20%. Concentration of OMR in rats’ plasma were determined after 2 h of the latest dose from 28 days multiple doses, p.o, 5 mg/kg/day. It was found to be 1295.66 ± 684.63 ng/mL estimated from the bio-analysis regression equation. OMR passed through the BBB following oral administration and exhibited concentration of 543.56 ± 344.15 ng/g in brain tissue, taking in consideration the dilution factor of 10. The brain/plasma concentration ratio of 0.42 (543.56/1295.66) was used to illustrate the penetration power through the BBB after the multiple doses for 28 days. Results showed that OMR passed through the BBB more effectively in the multiple dose study as compared to the previously published single dose study by the authors. Thus, the present study suggests potential repositioning of OMR as antiparkinsonian agent that will be of interest for researchers interested in neurodegenerative diseases." @default.
• W3126500640 created "2021-02-15" @default.
• W3126500640 creator A5016573101 @default.
• W3126500640 creator A5051064234 @default.
• W3126500640 creator A5067782292 @default.
• W3126500640 creator A5076390135 @default.
• W3126500640 creator A5082327300 @default.
• W3126500640 date "2021-02-08" @default.
• W3126500640 modified "2023-10-01" @default.
• W3126500640 title "Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS" @default.
• W3126500640 cites W1136751452 @default.
• W3126500640 cites W1276146532 @default.
• W3126500640 cites W1502077872 @default.
• W3126500640 cites W1563993585 @default.
• W3126500640 cites W1965019847 @default.
• W3126500640 cites W1967150171 @default.
• W3126500640 cites W1968186677 @default.
• W3126500640 cites W1977016037 @default.
• W3126500640 cites W1978297909 @default.
• W3126500640 cites W1979578990 @default.
• W3126500640 cites W1983756252 @default.
• W3126500640 cites W1985348186 @default.
• W3126500640 cites W1988307279 @default.
• W3126500640 cites W1990870506 @default.
• W3126500640 cites W1996132147 @default.
• W3126500640 cites W2000465889 @default.
• W3126500640 cites W2002917813 @default.
• W3126500640 cites W2005146299 @default.
• W3126500640 cites W2011430246 @default.
• W3126500640 cites W2012178932 @default.
• W3126500640 cites W2013794398 @default.
• W3126500640 cites W2016018886 @default.
• W3126500640 cites W2017430875 @default.
• W3126500640 cites W2018417599 @default.
• W3126500640 cites W2020603363 @default.
• W3126500640 cites W2027150840 @default.
• W3126500640 cites W2027519910 @default.
• W3126500640 cites W2035899318 @default.
• W3126500640 cites W2037226098 @default.
• W3126500640 cites W2040181124 @default.
• W3126500640 cites W2049710384 @default.
• W3126500640 cites W2051060071 @default.
• W3126500640 cites W2051728893 @default.
• W3126500640 cites W2056573366 @default.
• W3126500640 cites W2061583504 @default.
• W3126500640 cites W2062351818 @default.
• W3126500640 cites W2067736115 @default.
• W3126500640 cites W2075404533 @default.
• W3126500640 cites W2078374001 @default.
• W3126500640 cites W2081965230 @default.
• W3126500640 cites W2083952530 @default.
• W3126500640 cites W2090447931 @default.
• W3126500640 cites W2094109323 @default.
• W3126500640 cites W2097519488 @default.
• W3126500640 cites W2109728760 @default.
• W3126500640 cites W2122434726 @default.
• W3126500640 cites W2124658554 @default.
• W3126500640 cites W2133469996 @default.
• W3126500640 cites W2140454350 @default.
• W3126500640 cites W2142322475 @default.
• W3126500640 cites W2144862658 @default.
• W3126500640 cites W2146778032 @default.
• W3126500640 cites W2147817624 @default.
• W3126500640 cites W2155060077 @default.
• W3126500640 cites W2155287847 @default.
• W3126500640 cites W2164080605 @default.
• W3126500640 cites W2167183660 @default.
• W3126500640 cites W2169678694 @default.
• W3126500640 cites W2220062488 @default.
• W3126500640 cites W2269601075 @default.
• W3126500640 cites W2269721494 @default.
• W3126500640 cites W2296575546 @default.
• W3126500640 cites W2300093480 @default.
• W3126500640 cites W2311247123 @default.
• W3126500640 cites W2321646611 @default.
• W3126500640 cites W2367347012 @default.
• W3126500640 cites W2403324663 @default.
• W3126500640 cites W2460959997 @default.
• W3126500640 cites W2461157763 @default.
• W3126500640 cites W2464666556 @default.
• W3126500640 cites W2471590266 @default.
• W3126500640 cites W2473824958 @default.
• W3126500640 cites W2483090964 @default.
• W3126500640 cites W2510927034 @default.
• W3126500640 cites W2557645832 @default.
• W3126500640 cites W2561827752 @default.
• W3126500640 cites W2576833703 @default.
• W3126500640 cites W2593866083 @default.
• W3126500640 cites W2596421004 @default.
• W3126500640 cites W2609511098 @default.
• W3126500640 cites W2610960352 @default.
• W3126500640 cites W2614137535 @default.
• W3126500640 cites W2615406383 @default.
• W3126500640 cites W2625383462 @default.
• W3126500640 cites W2728248729 @default.
• W3126500640 cites W2761503357 @default.
• W3126500640 cites W2782493947 @default.
• W3126500640 cites W2799601288 @default.

• next